Takeda On Continued Lookout For Assets After Recent Deals
Reports Solid Q3 Results
Leading Japanese firm reports solid growth in its fiscal nine months as it hints more may be to come after recent major deals to expand the mid- to late-stage pipeline and highlights progress for some key internal assets.
You may also be interested in...
The US FDA approved Fruzaqla (fruquintinib) for previously treated metastatic disease regardless of biomarker status. The drug, already approved in China, was de-risked when Takeda licensed it from HutchMed.
South Korea’s Bridge Biotherapeutics aims to continue development of its first-in-class ulcerative colitis candidate BBT-401 despite its failure to meet the efficacy endpoint in a multinational Phase IIa study, and is also looking to progress other pipeline assets and out-licensing deals.
The drug beat out imatinib on efficacy while not drawing any increased concerns about safety, and an investigator told Scrip it should replace imatinib as first-line standard of care in the rare ALL subtype.